Cargando…
Case report: Long-lasting SARS-CoV-2 infection with post-COVID-19 condition in two patients with chronic lymphocytic leukemia: The emerging therapeutic role of casirivimab/imdevimab
Post-coronavirus disease 2019 (post-COVID-19) condition, previously referred to as long COVID, includes a post-acute syndrome defined by the presence of non-specific symptoms occurring usually 3 months from the onset of the acute phase and lasting at least 2 months. Patients with chronic lymphocytic...
Autores principales: | Ballotta, Laura, Simonetti, Omar, D’Agaro, Pierlanfranco, Segat, Ludovica, Koncan, Raffaella, Martinez-Orellana, Pamela, Dattola, Federica, Orsini, Emanuele, Marcello, Alessandro, Dal Monego, Simeone, Licastro, Danilo, Misin, Andrea, Mohamed, Sara, Sbisà, Eugenio, Lucchini, Elisa, De Sabbata, Giovanni Maria, Zaja, Francesco, Luzzati, Roberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561900/ https://www.ncbi.nlm.nih.gov/pubmed/36249044 http://dx.doi.org/10.3389/fonc.2022.945060 |
Ejemplares similares
-
Isolation and Full-Length Genome Characterization of SARS-CoV-2 from COVID-19 Cases in Northern Italy
por: Licastro, Danilo, et al.
Publicado: (2020) -
Discriminatory Value of Adiponectin to Leptin Ratio for COVID-19 Pneumonia
por: Tonon, Federica, et al.
Publicado: (2022) -
Casirivimab/Imdevimab: First Approval
por: Deeks, Emma D.
Publicado: (2021) -
Casirivimab and imdevimab for COVID-19
Publicado: (2022) -
Long-term decay of anti-RBD IgG titers after BNT162b2 vaccination is not mirrored by loss of neutralizing bioactivity against SARS-CoV-2
por: Malipiero, Giacomo, et al.
Publicado: (2022)